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Objectives: To compare the effect of tigecycline monotherapy, a first-in-class,
expanded broad spectrum glycylcycline, with the combination of vancomycin and
aztreonam (V + A) in the treatment of complicated skin and skin structure infections
(cSSSI).
Methods: A phase 3, double-blind study conducted in 8 countries enrolled adults with
cSSSI who required intravenous (IV) antibiotic therapy for 5 days. Patients were
randomly assigned (1:1) to receive either tigecycline or V + A for up to 14 days.
Primary endpoint was the clinical cure rate at the test-of-cure visit. Secondary
endpoints included microbiologic efficacy and in vitro susceptibility to tigecycline
of bacteria that cause cSSSI. Safety was assessed by physical examination, laboratory
analyses, and adverse event reporting.
Results: A total of 596 patients were screened for enrollment, 573 were analyzed for
safety, 537 were included in the clinical modified intent-to-treat (c-mITT) population,80 23228169; fax: +91 80 23228169.
ahoo.com (S. Sacchidanand), ellise@wyeth.com (E. Ellis-Grosse).
ional Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
252 S. Sacchidanand et al.397 were clinically evaluable (CE), and 228 were microbiologically evaluable (ME). At
test-of-cure, cure rates were similar between tigecycline and V + A groups in the CE
population (82.9% versus 82.3%, respectively) and in the c-mITT population (75.5%
versus 76.9%, respectively). Microbiologic eradication rates (subject level) at test-of-
cure in the ME population were also similar between tigecycline and V + A. Frequency
of adverse events was similar between groups, although patients receiving tigecycline
had higher incidence of nausea, vomiting, dyspepsia, and anorexia, while increased
ALT/SGPT, pruritis, and rash occurred significantly more often in V + A-treated
patients.
Conclusions: This study demonstrates that the efficacy of tigecycline monotherapy
for the treatment of patients with cSSSI is statistically noninferior to the combination
of V + A.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Complicated skin and skin structure infections
(cSSSI) are often polymicrobial in origin, occurring
in patients with preexisting skin lesions or under-
lying comorbid conditions. Patients with cSSSI fre-
quently require hospitalization and parenteral
antibiotic therapy.1 With the emergence of multi-
drug-resistant organisms during the last decade,
therapeutic options have become limited, espe-
cially when resistance develops to previously sus-
ceptible organisms.2,3 Since the early 1980s, the
number of newly approved antibacterial agents
in the USA has decreased substantially, and rela-
tively few are currently in development.4 Thus,
there is an increasing clinical need for new therapies
that are effective against resistant strains of micro-
organisms.
Tigecycline is a broad spectrum glycylcycline anti-
biotic5 with potent inhibition of bacterial protein
synthesis and cell growth.6 Tigecycline was designed
to circumvent two common drug-resistance mechan-
isms of bacteria: efflux and ribosomal protection.7 In
vitro studies have demonstrated strong activity
against a wide range of Gram-positive and Gram-
negative pathogens, including methicillin-resistant
and methicillin-susceptible Staphylococcus aureus
(MRSA and MSSA, respectively), penicillin-resistant
Streptococcus pneumoniae, Escherichia coli, Hemo-
philus influenzae, Enterococcus faecalis, Enterococ-
cus faecium, Moraxella catarrhalis, Bacteroides
spp., and Neisseria gonorrheae.8—11
A preliminary, phase 2, randomized study of hos-
pitalized patients with cSSSI demonstrated the clin-
ical and microbiologic efficacy of tigecycline at both
50 mg and 25 mg doses.12 Further, the phase 2 study
showed that tigecycline was well tolerated and had
a favorable pharmacokinetic profile. Tigecycline has
demonstrated activity against a broad spectrum of
pathogens frequently associated with cSSSI, includ-ing Gram-positive (Staphylococcus aureus, Strepto-
coccus pyogenes, Enterococcus faecalis) and Gram-
negative (E. coli) bacteria.8,13—15
Tigecycline’s activity against resistant organisms,
as well as its significant coverage of both Gram-posi-
tive andGram-negative bacteria,mayprovide a valu-
able therapeutic alternative in treating patientswith
cSSSI. Based on the results of phase 1 and phase 2
clinical studies, a largephase3 trialwas conducted to
assess the safety and efficacy of tigecycline (50 mg)
plus placebo compared with the combination of van-
comycin and aztreonam (V + A) in treating patients
withcSSSI.Vancomycin isactiveagainstawidevariety
of Gram-positive pathogens and is indicated for the
treatment of serious or severe skin infections, includ-
ing those caused by susceptible strains of MRSA.16
Vancomycin, however, lacks appreciable activity
against Gram-negative microorganisms, and thus
aztreonam was added to the comparator regimen.
Aztreonam is indicated for treatment of cSSSI and
other infectionscausedbysusceptibleGram-negative
microorganisms.17Weconductedthepresentphase3,
double-blind, randomized trial to compare the effect
of tigecycline monotherapy with the combination of
V + A in hospitalized patientswith skin and skin struc-
ture infections.Methods
Patient population
Men and women 18 years of age who required
intravenous (IV) antibiotic therapy for 5 days for
known or suspected cSSSI were eligible for study
participation. Complicated SSSI included infections
involving deep soft tissue or requiring significant
surgical intervention, including extensive cellulitis
of at least 10 cm in width or length, or those asso-
ciated with a significant underlying disease state
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complicates response to treatment. Patients were
eligible for enrollment if they exhibited at least two
of the following signs and symptoms of infection:
(1) drainage and/or discharge; (2) fever >37.8 8C
(100 8F) within 24 h before enrollment; (3)
erythema; (4) swelling and/or induration; (5) loca-
lized warmth; (6) pain and/or tenderness to palpa-
tion; or (7) white blood cell count >10  109/L.
Primary exclusion criteria included pregnant or
breastfeeding women, patients with severely
impaired arterial blood circulation who were likely
to require amputation, those with infected diabetic
foot ulcers or decubitus ulcers for >1 week, necro-
tizing fasciitis or gangrene, uncomplicated SSSI
infections (e.g., simple abscesses, folliculitis,
impetiginous lesions), and osteomyelitis contiguous
to the infected site. Patients with clinical suspicion
of ecthyma gangrenosum and those with known or
suspected hypersensitivities to tigecycline, tetra-
cyclines, minocycline, vancomycin, aztreonam, or
related antibiotics, hepatic disease, neutropenia,
calculated creatinine clearance <30 mL/min, and
patients receiving any investigational drugs within 4
weeks before study drug administration were also
excluded. Patients were excluded if they had a
known or suspected concomitant infection requiring
treatment with additional antibacterial agents or if
their SSSI could be treated by surgery alone.
Study design
This randomized, double-blind, phase 3 trial was
designed to compare the safety and efficacy of
tigecycline monotherapy with the combination of
V + A in patients with cSSSI. The trial was conducted
at 89 centers in 8 countries in North America, South
America, and India (USA, Canada, Argentina, Chile,
Guatemala, Mexico, Peru, and India). Each center
received approval from its institutional review
board or independent ethics committee, and all
patients provided written informed consent. This
study was conducted in accordance with the ethical
principles of the Declaration of Helsinki.
Patients were randomly assigned (1:1) to receive
either tigecycline with placebo or the combination
of V + A intravenously for up to 14 days. The rando-
mization schedule was generated by the Biostatis-
tics Department of Wyeth Research (Collegeville,
PA, USA). Study medications were administered in a
double-blind fashion or through an unblinded dis-
penser who did not participate in the direct evalua-
tion of patient efficacy or safety endpoints.
Patients randomly assigned to tigecycline
received an initial 100 mg dose, followed by
50 mg twice daily (approximately every 12 h) there-after, in a volume of 250 mL normal saline infused
over a 60 minute period. After each tigecycline
infusion, patients received 100 mL normal saline
placebo infused over another 60 minute period.
Patients randomly assigned to V + A received
twice-daily IV administration (approximately every
12 h) of 1 g vancomycin in 250 mL of normal saline
over a 60 minute period, followed by 2 g aztreonam
in 100 mL normal saline over another 60 minute
period. Infusion bags and tubing were covered to
obscure the color of tigecycline in solution in order
to maintain the blind.
Patients were allowed to receive standard treat-
ment for any stable, acute, or chronic medical
condition. Wound irrigation with sterile water or
saline solution, or topical antiseptics such as sulfa-
diazine, mafenide acetate, polyvidone iodine,
chlorhexidine, hydrogen peroxide, or Dakin’s solu-
tion was permitted. Patients could also receive daily
de´bridements or operative procedures as necessary
based on standard of care. However, the use of
topical antibacterials, steroids, and any nonstudy
antibacterials or other investigational therapies was
prohibited.
Populations analyzed
Patients were initially screened for enrollment in
the study, and those who met eligibility criteria
were randomly assigned to treatment and com-
prised the intent-to-treat (ITT) population. The
modified ITT (mITT) population consisted of patients
in the ITT population who received at least one dose
of study drug. Patients in the mITT population who
had clinical evidence of cSSSI comprised the clinical
mITT (c-mITT) population. The microbiologic mITT
(m-mITT) population consisted of patients in the
c-mITT population who had 1 isolate identified
at baseline. The clinically evaluable (CE) population
consisted of c-mITT patients who did not have Pseu-
domonas aeruginosa as a baseline primary isolate,
did not receive concomitant antibiotics after the
first dose of tigecycline, and who met criteria for
either clinical cure or failure at the test-of-cure
visit. The microbiologic evaluable (ME) population
consisted of CE patients who had an identifiable
primary isolate(s) that was susceptible to both study
drugs and who had clinical and microbiologic out-
comes (i.e., eradication, persistence, or superinfec-
tion) at the test-of-cure visit.
Efficacy endpoints
The primary efficacy endpoint was a clinical
response in the CE and c-mITT populations at the
test-of-cure visit. Clinical response was defined as
254 S. Sacchidanand et al.cure (i.e., resolution or improvement of signs and
symptoms of infection to the extent that no further
antibacterial therapy was required), failure (i.e.,
lack of response necessitating additional antibac-
terial therapy, extirpative surgical intervention,
death due to infection>2 days after randomization,
discontinuation due to treatment-related adverse
event, or receipt of >120% of prescribed treat-
ment), or indeterminate (i.e., lost to follow-up,
death <2 days after randomization or death not
related to infection before test-of-cure visit, no
clinical response at test-of-cure assessment).
Secondary efficacy variables included clinical
responses (cure or failure) and microbiologic
responses at the patient level (eradication, persis-
tence, superinfection, indeterminate) and isolate
level (eradication, persistence, indeterminate) for
patients in the ME and m-mITT populations at the
test-of-cure assessments.
Bacterial cultures were obtained from the pri-
mary site of infection and were sent to local micro-
biology laboratories for identification. Local
laboratories tested aerobic isolates for susceptibil-
ity to V + A by their standard techniques and to
tigecycline by disk diffusion. All isolates recovered
were subcultured and sent to a central laboratory
(Covance Central Laboratory Services Inc., Indiana-
polis, IN, USA) for isolate confirmation. Antimicro-
bial susceptibility testing was done by both the
Kirby—Bauer disk diffusion method and by the
microbroth dilution method to determine the mini-
mum inhibitory concentration (MIC) using proce-
dures published by the National Committee for
Clinical Laboratory Standards (NCCLS).18—20 Provi-
sional MIC breakpoints for tigecycline were deter-
mined from microbiologic samples obtained in
previous clinical investigations: 2 mg/mL for sus-
ceptible, 4 mg/mL for intermediate, and 8 mg/mL
for resistant. MIC50 and MIC90 represent the minimal
concentration of antibiotic that inhibited the
growth of 50% and 90% of the isolates, respectively.
Organisms isolated from baseline cultures were
considered to be the primary baseline isolates based
on the frequency with which those organisms are
identified in the particular disease state.21—25
Safety evaluation
All patients who received at least one dose of study
drug (mITT population) were evaluated for safety
and were monitored for adverse events. Safety
assessments included a physical examination and
12-lead electrocardiograms (ECGs) at baseline. At
each scheduled evaluation, vital signs (tempera-
ture, heart rate, blood pressure) and clinical labora-
tory parameters (hematology, serum chemistryevaluations, and coagulation profiles) were
assessed. Adverse events (AEs) and treatment-
emergent AEs (TEAEs), i.e., AEs that occurred or
worsened during treatment, were recorded
throughout the study period. Because renal failure
is a frequent complication of bacteremia in hospi-
talized patients,26 vancomycin dosage could be
adjusted according to creatinine clearance levels
for patients with compromised renal function as
suggested by the vancomycin label.16 Serum crea-
tinine levels were determined at baseline, on days
3, 7, and 14, or last day of therapy, and at the test-
of-cure visit. There was no requirement for mon-
itoring vancomycin levels. For patients who
required vancomycin dose adjustments, an
unblinded dispenser, who did not participate in
direct evaluation of the efficacy or safety endpoints
and did not interact with the patients, performed
the adjustments.
Statistical analyses
Clinical and microbiologic responses to tigecycline
and V + A were evaluated by using a 2-sided 95%
confidence interval (CI) for the true difference in
efficacy (i.e., tigecycline response rate minus V + A
response rate). Noninferiority was concluded if the
lower limit of the 2-sided 95% CI for the difference in
efficacy was no larger than15%. For all subpopula-
tion analyses (e.g., subgroup analyses, monomicro-
bial versus polymicrobial), an adjusted difference
between treatment groups with its 95% CI was cal-
culated from a generalized linear model with a
binomial probability function and an identity link
(SAS1 Proc GENMOD). The method of Wilson27 was
used for endpoints involving comparisons of tigecy-
cline and V + A with small sample sizes. The ‘exact’
method of Clopper and Pearson28 was used to com-
pute the 2-sided 95% CI for a single proportion. The
level of significance was set at 0.05.Results
A total of 573 patients received at least one dose of
study drug (mITT population) and were evaluated
for safety; 292 were randomly assigned to tigecy-
cline and 281 were randomly assigned to V + A
(Figure 1). Patients were well matched between
groups, and statistically significant differences in
demographic characteristics between treatment
groups (Table 1) did not exist. In both treatment
groups, the predominant clinical diagnosis was deep
soft tissue infection (62.0%), followed by major
abscesses (28.6%). Overall, 51.7% of infections were
spontaneous in nature, 26.9% were caused by
Tigecycline in skin infections 255
Figure 1 Study populations for analysis. See text for definitions of each population.trauma, and 10.8% resulted from surgery. Approxi-
mately 30% of patients in each group had diabetes.
Significant differences were not observed between
groups in themean number of study drug doses, days
on therapy, or mean calculated creatinine clearance
values.
Concomitant antibiotics were given to signifi-
cantly more patients in the V + A group (45 patients,
16.0%) than in the tigecycline group (30 patients,
10.3%; p = 0.047). These primarily consisted of beta-
lactam antibacterials (n = 22, 3.8%) and antibacter-
ials for topical use (n = 21, 3.7%). Additionally, 6
patients in theV + A group andnone in the tigecycline
group received concomitant quinolone antibiotics.
The use of concomitant antibiotics was consideredbefore the data were unblinded when determining
which patients were clinically evaluable.
Clinical outcomes
Test-of-cure assessments were performed within 12
to 92 days following the end of treatment. A total of
199 tigecycline-treated patients and 198 V + A-trea-
ted patients completed therapy and comprised the
CE population. Breaking the blind was the most
common reason for exclusion from the CE popula-
tion (8.9%). However, the blind was not broken for
failure to respond.
At the test-of-cure visit, cure rates were not
significantly different between treatment groups
256 S. Sacchidanand et al.
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Table 1 Patient demographics and baseline charac-
teristics (mITT population).
Tigecycline
(n = 292)
V + A
(n = 281)
Age, years, mean (SD) 49.4 (15.4) 48.4 (16.6)
Sex, n (%)
Men 180 (61.6) 188 (66.9)
Women 112 (38.4) 93 (33.1)
Ethnic origin, n (%)
White 154 (52.7) 149 (53.0)
Black 28 (9.6) 23 (8.2)
Asian 1 (0.3) 2 (0.7)
Hispanic 54 (18.5) 53 (18.9)
Other 55 (18.8) 54 (19.2)
Weight, kg, mean (SD) 81.5 (22.9) 82.0 (27.0)
Creatinine clearance,
mL/min, mean (SD)
109.5 (47.1) 110.1 (64.2)
Chief clinical diagnosis, n (%)
Deep soft tissue
infection
174 (59.6) 181 (64.4)
Cellulitis 161 (55.1) 169 (60.1)
Complicated
underlying
disease
56 (19.2) 60 (21.4)
10 cm (where
anatomically
applicable)
141 (48.3) 145 (51.6)
Requiring
surgery/drainage
73 (25.0) 77 (27.4)
Wound infection 13 (4.5) 12 (4.3)
Major abscesses 88 (30.1) 76 (27.0)
Infected ulcers 17 (5.8) 13 (4.6)
Infected Burns 2 (0.7) 6 (2.1)
Other 11 (3.8) 5 (1.8)
Cause of infection, n (%)
Trauma 71 (24.3) 83 (29.5)
Spontaneous 159 (54.5) 137 (48.8)
Bite (human,
insect, animal)
21 (7.2) 17 (6.0)
Surgery 30 (10.3) 32 (11.4)
Injection 7 (2.4) 8 (2.8)
Other 4 (1.4) 4 (1.4)
Number of doses,
mean (SD)
14.7 (6.4) 15.4 (6.8)
Days on therapy,
mean (SD)
8.2 (3.3) 8.6 (3.4)
Comorbidity conditions, n (%)
Diabetes mellitus 89 (30.5) 82 (29.2)
Peripheral vascular
disease
28 (9.6) 18 (6.4)in the CE population (Table 2); 82.9% of patients
receiving tigecycline monotherapy were cured by
the test-of-cure visit. This success rate was compar-
able with that in patients treated with the V + A
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Table 3 Clinical success rates in the CE population at the test-of-cure visit by baseline diagnosis, and in patients with
diabetes, peripheral vascular disease, or baseline bacteremia.
Baseline diagnosis Tigecycline V + A Difference
(tigecycline — V + A)
n/N % (95% CI) n/N % (95% CI) % (95% CI)
Soft tissue infections 109/133 82.0 (74.4, 88.1) 118/141 83.7 (76.5, 89.4) 1.7 (11.3, 7.7)
Abscesses 43/50 86.0 (73.3, 94.2) 33/41 80.5 (65.1, 91.2) 5.5 (11.3, 23.1)
Infected ulcers 9/12 75.0 (42.8, 94.5) 7/11 63.6 (30.8, 89.1) 11.4 (28.8, 48.2)
Burns 0/0 NA 1/1 100.0 (2.5, 100.0) NA
Other 4/4 100.0 (39.8, 100.0) 4/4 100.0 (39.8, 100.0) 0.0 (60.4, 60.4)
Comorbidity
Diabetes 39/58 67.2 (53.7, 79.0) 42/58 72.4 (59.1, 83.3) 5.2 (22.5, 12.5)
Peripheral vascular disease 15/19 78.9 (54.4, 93.9) 11/16 68.8 (41.3, 89.0) 10.2 (21.3, 40.9)
Baseline bacteremia 5/8 62.5 (24.5, 91.5) 11/14 78.6 (49.2, 95.3) 16.1 (55.9, 24.3)
NA: not applicable.combination (82.3%) and demonstrates that the effi-
cacy of tigecycline monotherapy was statistically
noninferior to the combination of V + A (difference
tigecycline — V + A % (95% CI) = 0.6% (7.4,8.6), p-
value for noninferiority <0.001, p-value for differ-
ences = 0.9816). Tigecycline also met the statisticalTable 4 Microbiologic response at the test-of-cure visit fo
Response Tigecycline V + A
n/N % (95% CI) n/N % (95%
Eradication 90/115 78.3 (69.6, 85.4) 87/113 77.0 (6
Monomicrobial 55/71 77.5 (66.0, 86.5) 53/69 76.8 (6
Polymicrobial 35/44 79.5 (64.7, 90.2) 34/44 77.3 (6
Persistence 20/115 17.4 22/113 19.5
Monomicrobial 14/71 19.7 14/69 20.3
Polymicrobial 6/44 13.6 8/44 18.2
Superinfection 5/115 4.3 4/113 3.5
Monomicrobial 2/71 2.8 2/69 2.9
Polymicrobial 3/44 6.8 2/44 4.5
Table 5 Microbiologic response for selected baseline isola
Isolatea Tigecycline
n/N % (9
Enterococcus faecalisb 5/6 83.3 (3
Escherichia coli 4/6 66.7 (2
Staphylococcus aureus 46/56 82.1 (6
MRSA 16/21 76.2 (5
MSSA 30/35 85.7 (6
Streptococcus agalactiae 3/3 100.0 (2
Streptococcus pyogenes 6/7 85.7 (4
MRSA: methicillin-resistant Staphylococcus aureus. MSSA: methicill
a Although Bacteroides fragiliswas a selected primary pathogen, th
organism.
b In this study, all E. faecalis primary isolates were susceptible tocriteria for noninferiority to V + A in the c-mITT
population (difference tigecycline — V + A % (95%
CI) = 1.5% (9.0,6.1) p-value for noninferiority
<0.001, p-value for differences = 0.7650). Specifi-
cally, in the CE and c-mITT populations, the lower
limit of the 95% CI for the true difference betweenr patients in the ME population.
Difference (tigecycline — V + A)
CI) % (95% CI) Test for
noninferiority
Test for
difference
8.1, 84.4) 1.3 (10.4, 13.0) 0.0026 0.9433
5.1, 86.1) 0.7 (14.1, 15.5)
2.2, 88.5) 2.3 (16.4, 20.8)
tes at test-of-cure visit in the ME population.
Vancomycin/aztreonam
5% CI) n/N % (95% CI)
5.9, 99.6) 4/7 57.1 (18.4, 90.1)
2.3, 95.7) 2/4 50.0 (6.8, 93.2)
9.6, 91.1) 49/59 83.1 (71.0, 91.6)
2.8, 91.8) 17/21 81.0 (58.1, 94.6)
9.7, 95.2) 32/38 84.2 (68.7, 94.0)
9.2, 100.0) 7/9 77.8 (40.0, 97.2)
2.1, 99.6) 6/8 75.0 (34.9, 96.8)
in-susceptible Staphylococcus aureus. NA: not applicable.
erewere less than five total isolates so data are not given for this
vancomycin.
258 S. Sacchidanand et al.
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.treatments was 7.4% and 9.0%, respectively, at
test-of-cure visit. Results in the ME and m-mITT
populations were consistent with findings of nonin-
feriority of tigecycline in the CE and c-mITT popula-
tions (Table 2).
When analyzed by clinical diagnosis, such as soft
tissue infections and major abscesses, cure rates
were also comparable between groups (Table 3).
Tigecycline monotherapy was comparable with
V + A in the subsets of patients with baseline diag-
noses of diabetes, peripheral vascular disease, or
bacteremia.
Microbiologic responses
Eradication rates at the patient level were compar-
able between treatment groups, demonstrating the
noninferiority of tigecycline monotherapy to the
combination of V + A in eradicating skin infections
in the ME (Table 4) and m-mITT (data not shown)
populations. Although differences in eradication
rates between groups were adjusted for type of
infection, these differences were similar to unad-
justed differences. Because of the small sample
size, microbiologic response of failures were pooled
with a similar phase 3 study and analyzed. The
results of this pooled analysis will be summarized
in a separate manuscript. Eradication rates of
selected primary baseline isolates commonly asso-
ciated with cSSSI were high in both treatment
groups (Table 5); for MRSA, eradication rates were
76.2% for the tigecycline group and 81.0% for the
V + A group.
MIC testing was used to evaluate the sensitivity of
the selected primary baseline isolates commonly
associated with cSSSI and the sensitivity of other
isolates to tigecycline, vancomycin, and aztreonam.
Over the course of this study, there was no evidence
of the development of decreased susceptibility to
tigecycline. Although the number of isolates avail-
able for analysis was small, bacterial susceptibilities
to tigecycline appeared to be consistent with clin-
ical responses. MIC90 values for tigecycline mono-
therapy were uniformly low for the most prevalent
isolates, including MRSA and MSSA, compared with
the V + A combination (Table 6).
Safety
Both tigecycline and V + A were well tolerated
and the overall frequency of treatment-emergent
adverse events was similar between treatment
groups (Table 7). Only a small percentage of patients
discontinued treatment because of adverse events:
18 patients (6.2%) in the tigecycline group and
13 patients (4.6%) in the V + A group in the mITT
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Table 7 Treatment emergent adverse events that
occurred in 3% of patients, number of patients (%).
Body system adverse event Tigecycline
(n = 292)
V + A
(n = 281)
Any adverse eventa 240 (82.2) 218 (77.6)
Body as a whole 111 (38.0) 94 (33.5)
Abdominal pain 13 (4.5) 7 (2.5)
Chills 9 (3.1) 3 (1.1)
Fever 11 (3.8) 21 (7.5)
Headache 36 (12.3) 26 (9.3)
Infection 7 (2.4) 10 (3.6)
Pain 24 (8.2) 13 (4.6)
Cardiovascular systemb 34 (11.6) 55 (19.6)
Hypertension 7 (2.4) 11 (3.9)
Phlebitis 7 (2.4) 16 (5.7)
Digestive systemb 169 (57.9) 75 (26.7)
Anorexiab 12 (4.1) 2 (0.7)
Constipation 8 (2.7) 15 (5.3)
Diarrhea 37 (12.7) 24 (8.5)
Dyspepsiab 16 (5.5) 5 (1.8)
Nauseab 126 (43.2) 31 (11.0)
Vomitingb 78 (26.7) 14 (5.0)
Hemic and lymphatic system 49 (16.8) 42 (14.9)
Activated partial
thromboplastin
time prolonged
18 (6.2) 8 (2.8)
Anemia 6 (2.1) 11 (3.9)
Prothrombin time prolonged 14 (4.8) 5 (1.8)
Thrombocythemia 11 (3.8) 9 (3.2)
Metabolic and nutritional 61 (20.9) 67 (23.8)
Amylase increased 9 (3.1) 3 (1.1)
Hyperglycemia 7 (2.4) 11 (3.9)
Hypokalemia 7 (2.4) 9 (3.2)
Lactic dehydrogenase
increased
9 (3.1) 3 (1.1)
AST/SGOT increased 6 (2.1) 14 (5.0)
ALT/SGPT increasedb 3 (1.0) 16 (5.7)
Musculoskeletal system 12 (4.1) 12 (4.3)
Nervous system 34 (11.6) 41 (14.6)
Dizziness 14 (4.8) 10 (3.6)
Insomnia 8 (2.7) 14 (5.0)
Respiratory system 23 (7.9) 32 (11.4)
Cough increased 10 (3.4) 8 (2.8)
Dyspnea 5 (1.7) 11 (3.9)
Skin and appendagesb 40 (13.7) 69 (24.6)
Pruritis b 13 (4.5) 30 (10.7)
Rashb 8 (2.7) 22 (7.8)
Special senses 6 (2.1) 10 (3.6)
Urogenital system 17 (5.8) 13 (4.6)
Others 16 (5.5) 15 (5.3)
Local reaction
to procedure
16 (5.5) 11 (3.9)
a Patients may have had more than 1 treatment-emergent
adverse event.
b Significant between-group difference (p < 0.05).population. Nausea was the most common adverse
event that led to discontinuation of study therapy
among tigecycline-treated patients, whereas prur-
itis and rash were the most common adverse events
that led to discontinuation in the V + A group. Of
note, patients receiving V + A had a significantly
higher incidence of pruritis, rash, and elevated
ALT/SGPT levels compared with patients receiving
tigecycline, whereas tigecycline-treated patients
had significantly a higher incidence of nausea and
vomiting, as well as anorexia and dyspepsia. No
tigecycline-treated patient had a positive Clostri-
dium difficile toxin assay, nor developed C. difficile-
associated diarrhea.
Five deaths occurred in the tigecycline group:
two occurred more than one week after completion
of therapy, one resulted from a prestudy condition
(sepsis), one from unrelated complications (acute
renal failure/cardiogenic shock) that occurred on
the first and second day of therapy, and one resulted
from a perforated ulcer. One death in the V + A
group resulted from chronic obstructive pulmonary
disease and congestive heart failure. No deaths
were considered to be related to the use of the
study drug. There were no clinically important
changes from baseline in laboratory parameters,
vital signs, or ECGs. Most laboratory changes were
small, with means remaining within normal biologic
ranges.Discussion
This phase 3 randomized and double-blind trial
demonstrated that the efficacy of tigecycline mono-
therapy was comparable with that of the combina-
tion of V + A in the treatment of patients with cSSSI.
Subgroup analyses also found that success rates
were similar with tigecycline monotherapy and
combination V + A treatment among those patients
with underlying diabetes, peripheral vascular dis-
ease, and bacteremia. In a previously reported
phase 2 trial of hospitalized patients with cSSSI
receiving 50 mg of tigecycline, patients had a clin-
ical cure rate of 74% at test-of-cure assessment.12
Although similar to the phase 2 trial results, the cure
rate in the present phase 3 study is higher (82.9%) in
the clinically evaluable population (Table 2).
Tigecycline monotherapy was statistically nonin-
ferior to the combination of V + A, based on the
lower boundary of the 2-sided CI (7.4%) in the CE
population for the difference in cure rate. Nonin-
feriority of tigecycline to V + Awas demonstrated by
cure rates in the CE and c-mITT populations, by
microbiologic responses of patients in the ME and
m-mITT populations, and by microbiologic efficacy
260 S. Sacchidanand et al.responses of isolates. Further, eradication rates
appeared to correlate well with clinical cure rates.
Tigecycline demonstrated microbiologic efficacy
against a broad spectrum of both Gram-positive
and Gram-negative microorganisms commonly iden-
tified in patients with cSSSI, including Staphylococ-
cus aureus (MRSA and MSSA), Enterococcus faecalis,
E. coli, Streptococcus agalactiae, and Streptococcus
pyogenes. Provisional MIC breakpoints for tigecy-
cline were established prior to study start from
microbiologic samples obtained in previous clinical
investigations. MIC90 values for tigecycline were
uniformly low for the most prevalent isolates,
including MRSA and MSSA (MIC90 = 0.25 mg/mL for
both). During the study period, there was no evi-
dence of the development of decreased susceptibil-
ity to tigecycline.
Tigecycline and V + A were shown to be safe and
well tolerated. Patients receiving the V + A combina-
tion experienced significantly higher incidences of
pruritis, rash, and elevated levels of ALT/SGPT than
patients receiving tigecycline monotherapy.
Although the incidence of nausea and vomiting was
significantly higher in tigecycline-treated patients,
the severitywasmild tomoderate, andmost patients
did not discontinue treatment because of these
events. An earlier report demonstrated that patient
tolerance of tigecycline was improved when the drug
was administered with food.29
Tigecycline offers potential advantages over other
parenterally administered antimicrobial agents
because of its expanded spectrum of coverage
against Gram-positive, anaerobic, Gram-negative,
andmultiply antimicrobial resistantmicroorganisms.
The current standard of care for cSSSI may require an
approach using either a very broad spectrum anti-
microbial agent or multiple agents used in combina-
tion in order to provide antibacterial activity against
both Gram-positive and Gram-negative isolates.30,31
Unlike vancomycin, tigecycline’s spectrum of anti-
bacterial activity does not cause it to require addi-
tional antimicrobial agents for Gram-negative
coverage. Since tigecycline monotherapy provides
activity against Gram-positive and Gram-negative
microorganisms as well as anaerobes and certain
antimicrobial resistant pathogens,8,13—15,32—35 only
one antimicrobial agent needs to be administered.
Compared with the V + A combination treatment,
tigecycline monotherapy appears to be safe and
efficacious in the treatment of patients with
cSSSI and is a promising agent for the treatment of
cSSSI.
These results were presented in part at the 11th
International Symposium on Staphylococci & Sta-
phylococcal Infections, October 24—27, 2004, Char-
leston, South Carolina, USA, Control #TH-13.Acknowledgments
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